Jerry Pelletier Laboratory
Department of Biochemistry and The Rosalind and Morris Goodman cancer Centre
Publications
Selected Recent Publications
-Chu, J., Zhang, W., Cencic, R., O’Connor, P.B.F., Robert, F., Devine, W.G., Selznick, A., Henkel, T., Merrick, W.C., Brown, LE., Baranov, P., Porco, Jr., J.A., and Pelletier, J. (2020) Rocaglates induce gain-of-function alterations to eIF4A and eIF4F. Cell Reports 30: 2481-2488
-Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C.J., Brown, L.E., Porco, J.A. Jr., Pollak, M., Larsson, O., Pelletier, J., Chio, I.I.C, (2019) eIF4A supports and oncogenic program in pancreatic ductal adenocarcinoma. Nat Comm. 10: 5151.
-Steinberger, J., Robert, F., Hallé, M., Williams, D.E., Cencic, R., Sawhney, N., Pelletier, D., Williams, P., Igarashi, Y., Rodriguez, A.D., Kopp, B., Bachmann, B., Andersen, R.J., and Pelletier, J. (2019) Tracing MYC Expression for Small Molecule Discovery. Cell Chem Biol, 26: 699-710.e6
-Itoua Maiga, R., Cencic, R., Chu, J., Waller, D.D., Brown, L.E., Devine, W.G., Zhang, W., Sebag, M., Porco, J.A. Jr., and Pelletier, J. (2019) Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation. Sci Report 9: 1265.
-Katigbak, A., Robert, F., Paquet, M., and Pelletier, J. (2018) Inducible genome editing with conditional CRISPR/Cas9 mice. G3. 8: 1627 – 1635
-Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J.R., Porco, Jr., J.A., and Pelletier, J. (2016). CRISPR-mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A. Cell Reports. 15: 2340 - 2347..
-Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., Da Silva, B., Yao, M., Gorton, F., Shi, J., Thomas, C.J., Brown, L.E., Porco, J.A. Jr., Pollak, M., Larsson, O., Pelletier, J., Chio, I.I.C, (2019) eIF4A supports and oncogenic program in pancreatic ductal adenocarcinoma. Nat Comm. 10: 5151.
-Steinberger, J., Robert, F., Hallé, M., Williams, D.E., Cencic, R., Sawhney, N., Pelletier, D., Williams, P., Igarashi, Y., Rodriguez, A.D., Kopp, B., Bachmann, B., Andersen, R.J., and Pelletier, J. (2019) Tracing MYC Expression for Small Molecule Discovery. Cell Chem Biol, 26: 699-710.e6
-Itoua Maiga, R., Cencic, R., Chu, J., Waller, D.D., Brown, L.E., Devine, W.G., Zhang, W., Sebag, M., Porco, J.A. Jr., and Pelletier, J. (2019) Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation. Sci Report 9: 1265.
-Katigbak, A., Robert, F., Paquet, M., and Pelletier, J. (2018) Inducible genome editing with conditional CRISPR/Cas9 mice. G3. 8: 1627 – 1635
-Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J.R., Porco, Jr., J.A., and Pelletier, J. (2016). CRISPR-mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A. Cell Reports. 15: 2340 - 2347..
-Malina, A., Robert, F., Jerry Pelletier (2015) PAM multiplicity marks genomic target sites as inhibitory to CRISPR/Cas9 editing. Nature Comm 6: 10124.
-Cencic, R., Miura, H., Malina, A., Robert, F., Schmeing, T.M., Dostie, J., and Pelletier, J. (2014) Protospacer Adjacent Motif (PAM)-Distal Sequences Engage CRISPR Cas9 DNA Target Cleavage PLoS ONE. 9: e109213.
-Malina, A., Mills, J., Cencic, R., Yan, Y., Scchippers, L.M., Paquet, M., Dostie,J., Pelletier, J., (2013) Repurposing CRISPR/Cas9 for In Situ Functional Assays. Genes & Dev. 27: 2602-2614.